This page summarizes anecdotal reports and community observations, not medical evidence. Reports may be incomplete, biased or inaccurate and are not medical advice or recommendations. “Risk” here refers to how frequently severe or prolonged symptom worsening is reported, not to proven causation or population-wide probability. Individual responses vary widely, and absence of issues in some users does not rule out significant reactions in others.

PFS/PSSD/PAS Community Context & Proposed Mechanism: Within PFS/PSSD/PAS communities, calcium D-glucarate (CDG) is discussed in relation to supporting Phase II glucuronidation, the detoxification pathway responsible for clearing steroid hormones, neurosteroid metabolites, and xenobiotics from the body. The theoretical rationale centers on CDG's metabolite, D-glucaro-1,4-lactone, which inhibits beta-glucuronidase: a gut and tissue enzyme that normally cleaves glucuronic acid off conjugated compounds and allows them to be reabsorbed rather than excreted with the proposed effect being a net increase in successful clearance of glucuronidated hormones and metabolites rather than their recirculation. Some in the community, including framing sometimes attributed to Dr. Powers' broader glucuronidation-centric model of PFS/PSSD, connect this to the hypothesis that persistent symptoms stem in part from impaired clearance of androgens and their downstream metabolites, making beta-glucuronidase inhibition a theoretically attractive lever though it's important to note this application has not been validated in controlled studies for PFS/PSSD/PAS and remains extrapolated from oncology/hormone-metabolism literature. As with other protocols in this framework, individual response may depend heavily on genetics particularly UGT enzyme status (e.g., UGT2B17 and UGT2B28, both frequently discussed in PFS genetic write-ups). Since CDG's action assumes conjugation is occurring upstream and simply needs protection from deconjugation, meaning it may do little for individuals whose primary bottleneck is insufficient glucuronidation capacity in the first place rather than excess deconjugation.

Mixed Results w/ crashes worsening baseline, windows & sustained Improvements. Moderate risk due to variable response.

May Depend on Individual Deficiency Pattern: In community experimentation, reports on calcium D-glucarate are inconsistent, some individuals describe crashes or worsening of symptoms after starting, others report temporary windows of improvement that faded, and a smaller subset report sustained improvement maintained over time. No anecdotes describe a full cure. The variability appears linked to individual differences in baseline glucuronidation capacity and beta-glucuronidase activity, those whose primary deficit is insufficient conjugation (rather than excess deconjugation/recirculation) may see no benefit or even a crash if CDG shifts hormone clearance dynamics in a direction their system isn't equipped to handle, while those with adequate conjugation but high deconjugation activity may be more likely to benefit.

Evidence basis: Scattered anecdotal reports across PFS/PSSD/PAS forums and self-report communities; established pharmacology of beta-glucuronidase inhibition and glucuronidation from oncology/hormone-metabolism literature; no controlled studies establishing safety or efficacy for PFS/PSSD/PAS specifically, and no biomarker-based method currently used in these communities to predict who will respond well versus crash.

Worsening Anecdote Link

Slight Improvement Anecdote Link